Biotech · Private company · San Diego, CA, US
Allakos Inc.
SEC CIK 0001564824
Track this companyFree. Adds Allakos Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials150 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- AK002Phase 3 · Eosinophilic DuodenitisClinicalTrials.gov · fetched Nov 12, 2026
- AK002Phase 3 · Eosinophilic GastritisClinicalTrials.gov · fetched Nov 12, 2026
- lirentelimabPhase 3 · Eosinophilic GastritisClinicalTrials.gov · fetched Nov 12, 2026
- lirentelimab (AK002)Phase 3 · Eosinophilic GastritisClinicalTrials.gov · fetched Nov 12, 2026
- lirentelimab (AK002)Phase 3 · Eosinophilic EsophagitisClinicalTrials.gov · fetched Nov 12, 2026
- AK001 high dosePhase 2 · Nasal PolyposisClinicalTrials.gov · fetched Nov 12, 2026
- AK001 low dosePhase 2 · Nasal PolyposisClinicalTrials.gov · fetched Nov 12, 2026
- AK002Phase 2 · Chronic UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- AK002Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Lirentelimab (AK002)Phase 2 · Chronic Spontaneous UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- AK002Phase 1 · Atopic KeratoconjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- AK006 IVPhase 1 · Chronic Spontaneous UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- AK006-IVPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- AK006-SCPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- lirentelimab (AK002)Phase 1 · Study Conducted in Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001PHASE1 · COMPLETED · started Aug 28, 2024ClinicalTrials.gov NCT06577116 · fetched Nov 12, 2026
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous UrticariaPHASE1 · COMPLETED · started Aug 28, 2023ClinicalTrials.gov NCT06072157 · fetched Nov 12, 2026
- A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous UrticariaPHASE2 · TERMINATED · started Oct 26, 2022ClinicalTrials.gov NCT05528861 · fetched Nov 12, 2026
- A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic DermatitisPHASE2 · TERMINATED · started Jun 27, 2022ClinicalTrials.gov NCT05155085 · fetched Nov 12, 2026
- A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic DuodenitisPHASE3 · WITHDRAWN · started Dec 1, 2021ClinicalTrials.gov NCT05152563 · fetched Nov 12, 2026
- A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic DuodenitisPHASE3 · COMPLETED · started May 20, 2021ClinicalTrials.gov NCT04856891 · fetched Nov 12, 2026
- An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)PHASE3 · COMPLETED · started Dec 3, 2020ClinicalTrials.gov NCT04620811 · fetched Nov 12, 2026
- A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic EsophagitisPHASE2_PHASE3 · COMPLETED · started Jul 6, 2020ClinicalTrials.gov NCT04322708 · fetched Nov 12, 2026
- A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)PHASE3 · COMPLETED · started Jun 18, 2020ClinicalTrials.gov NCT04322604 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy VolunteersPHASE1 · COMPLETED · started Mar 23, 2020ClinicalTrials.gov NCT04324268 · fetched Nov 12, 2026
- An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic DuodenitisPHASE2 · COMPLETED · started Nov 14, 2018ClinicalTrials.gov NCT03664960 · fetched Nov 12, 2026
- A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisPHASE2 · COMPLETED · started Jul 18, 2018ClinicalTrials.gov NCT03496571 · fetched Nov 12, 2026
- A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic ConjunctivitisPHASE1 · COMPLETED · started Feb 26, 2018ClinicalTrials.gov NCT03379311 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic UrticariaPHASE2 · COMPLETED · started Jan 23, 2018ClinicalTrials.gov NCT03436797 · fetched Nov 12, 2026
- Study to Evaluate Multiple Doses in Patients With Nasal PolyposisPHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02734849 · fetched Nov 12, 2026
SEC filings10
- 8-K · 8-KSEC EDGAR · filed May 15, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2025 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 17, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 13, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 27, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 27, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 18, 2024 · fetched Nov 12, 2026